ALTHX — Thx Pharma SA Share Price
0.000.00%
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 30.2 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -340.96% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Thx Pharma SA is a France-based pharmaceutical company specialized in the treatment of rare neurological diseases. The Company is an antisense oligonucleotide platform for the identification and characterization of therapy drug candidates co-constructed with laboratories in the field of neurological diseases. The first drug, TX01 for the disease of Niemann-Pick type C and Gaucher’s disease. The second drug, Batten-1, aims at the form juvenile of Batten disease and could be the first therapy considered in this form. It has marketed its drugs notably in Europe and also in the United States, Canada and Australia.
Directors
- Franck Mouthon CHM
- Mathieu Charveriat DCE
- Thierry Lambert CFO (65)
- Werner Rein OTH
- Julien Veys OTH
- Sebastien Descarpentries DRC
- Rodolphe Besserve IND
- Eric Doulat IND
- Jerome Martinez IND (51)
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- January 2nd, 2013
- Public Since
- October 30th, 2017
- No. of Employees
- 10
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 9,817,813.03
- Address
- 60, LYON, 69008
- Web
- https://www.theranexus.com/
- Phone
- +33 188897031
- Auditors
- Ernst & Young et Autres
Upcoming Events for ALTHX
Similar to ALTHX
Abionyx Pharma SA
Euronext - Paris
Abivax SA
Euronext - Paris
Adocia SA
Euronext - Paris
Biophytis SA
Euronext - Paris
Cellectis SA
Euronext - Paris
FAQ
What is the Thx Pharma SA share price?
As of Today at 22:42 UTC, shares in Thx Pharma SA are trading at €3.02. This share price information is delayed by 15 minutes.
How has the Thx Pharma SA share price performed this year?
Shares in Thx Pharma SA last closed at €3.02 and the price had moved by +646.07% over the past 365 days. In terms of relative price strength the Thx Pharma SA share price has outperformed the FTSE Global All Cap Index by +601.08% over the past year.
What are the analyst and broker recommendations for Thx Pharma SA?
The overall consensus recommendation for Thx Pharma SA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Thx Pharma SA dividend yield?
Thx Pharma SA does not currently pay a dividend.
Does Thx Pharma SA pay a dividend?
Thx Pharma SA does not currently pay a dividend.
When does Thx Pharma SA next pay dividends?
Thx Pharma SA does not currently pay a dividend.
How do I buy Thx Pharma SA shares?
To buy shares in Thx Pharma SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Thx Pharma SA?
As of the previous close price of €3.02, shares in Thx Pharma SA had a market capitalisation of €29.65m.
Where are Thx Pharma SA shares listed?
Here are the trading details for Thx Pharma SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: ALTHX
What kind of share is Thx Pharma SA?
Based on an overall assessment of its quality, value and momentum Thx Pharma SA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Thx Pharma SA share price forecast for 2026?
The analyst consensus target price for shares in Thx Pharma SA is €4.40. That is 45.7% above the last closing price of €3.02.
Analysts covering Thx Pharma SA currently have a consensus Earnings Per Share (EPS) forecast of -€0.10 for the next financial year.
Find out moreWhat is the trend in the Thx Pharma SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Thx Pharma SA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +32.51%.
As of the last closing price of €3.02, shares in Thx Pharma SA were trading +36.18% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Thx Pharma SA PE Ratio?
The Thx Pharma SA PE ratio based on its reported earnings over the past 12 months is 30.2. The shares last closed at €3.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Thx Pharma SA?
Thx Pharma SA's management team is headed by:
- Franck Mouthon - CHM
- Mathieu Charveriat - DCE
- Thierry Lambert - CFO
- Werner Rein - OTH
- Julien Veys - OTH
- Sebastien Descarpentries - DRC
- Rodolphe Besserve - IND
- Eric Doulat - IND
- Jerome Martinez - IND